Cooperative Agreement UG3DA062506
Award Date
7/1/25
Completion Date
6/30/27
Dollars Obligated
$2.1M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Washington, DC, USA
Similar Awards
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), has awarded a $23,579,701 Cooperative Agreement to Ensysce Biosciences, Inc. to support the clinical development of PF614-MPAR, an opioid product with oral overdose protection. The key objectives of this project are to continue the clinical development of PF614-MPAR, a combination product of a trypsin-activated abuse protection (TAAP) oxycodone prodrug and a trypsin inhibitor...
The National Institute on Drug Abuse (NIDA) awarded Resilient Lifescience, Inc. a $854,122 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop a wearable medical device that can detect opioid-induced respiratory depression and issue an emergency alert. The goal is to create a technology solution that can help ensure rapid administration of the life-saving drug naloxone when an opioid overdose occurs, particularly in situations where the individual is...
The National Institute on Drug Abuse (NIDA) awarded a $1,539,426 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Serodopa Therapeutics Inc. to develop a novel intranasal formulation of a naloxone derivative for the reversal of opioid-induced respiratory depression caused by high-potency opioids such as fentanyl. The project aims to complete formulation development, preclinical toxicology and safety testing required to prepare an Investigational New Drug (IND)...
This Project Grant award of $847,000 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to evaluate the therapeutic potential of neuropeptide S receptor 1 (NPSR1) agonism for reducing opioid self-administration and relapse in preclinical animal models. The research team at the University of Tennessee Health Science Center will leverage pharmacological tools to investigate NPSR1 as a novel target for treating...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding the development of ODALERT - an innovative wearable device designed to detect and alert users and first responders of potential opioid overdoses. The $800,000 award to Biosensics LLC, a digital health technology company, will support the completion of ODALERT's sensor development, optimization of battery life, deployment of real-time...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $419,876 to conduct preclinical trials targeting the neuropeptide S (NPS) receptor to mitigate opioid taking and seeking behaviors in animal models. The goals of the project are to demonstrate proof-of-concept that NPS receptor-targeted molecules can reduce oxycodone self-administration and motivation in rats, which could inform the...
This Project Grant award of $2,316,128.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to design tailored harm reduction strategies to address the opioid overdose crisis across six distinct jurisdictions. The project, titled "REVERSING OVERDOSE EPIDEMICS THROUGH SIMULATION, COLLABORATION, AND UNIFIED EFFORTS (RESCUE)", will collaborate with health departments and community partners to assess the...
The National Institute on Drug Abuse (NIDA) awarded a $11,811,988 Cooperative Agreement (CFDA 93.279 - Drug Use and Addiction Research Programs) to The University of Texas Health Science Center at San Antonio (UTHSCSA) on August 15, 2024. The 3-year project aims to continue developing the novel mu-opioid receptor antagonist Methocinnamox (MCAM) for preventing opioid relapse after detoxification. Key objectives include submitting an Investigational New Drug (IND) application, completing Phase 1...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $759,339 to The Trustees of the University of Pennsylvania to conduct research on the role of central amylin receptors in opioid-mediated behaviors. The key objectives are to: Comprehensively define the functional roles of cell type-specific ventral tegmental area (VTA) and nucleus accumbens (NAc) amylin receptors in opioid taking and seeking behaviors...